Morning Briefing

When the results of a large clinical trial testing the effectiveness of the RTS,S malaria vaccine among children in Africa are made available later this year, "it will be time to start discussing what to do with the vaccine," Orin Levine, executive director of the International Vaccine Access Center at Johns Hopkins University, writes in a Huffington Post opinion piece. "If the vaccine is safe and effective, one of the most important questions will be how to pay for it ... and even though Andrew Witty, the CEO of the vaccine's manufacturer, GSK, has promised to price the vaccine at a point just above its production cost, this price may still end up being too high for many malaria-affected countries to pay for it," he writes.